Research Insights
Research Insights section focuses on the cutting-edge and breakthrough research that is happening all over the world. Laboratories across the globe are working hard to develop drugs and therapies for various diseases and research insights directly from them add tremendous value.
AI-first Structural Identification of Pathogenic Protein Target Interfaces
The risk of pandemics is increasing as global population growth and interconnectedness accelerate Understanding the structural basis of proteinprotein interactions between pathogens and hosts is critical
A Mathematical Framework for the Quantitative Analysis of Genetic Buffering
Genetic buffering plays a pivotal role in orchestrating the relationship between genotype and phenotype in outbred populations While highthroughput screens have identified many instances of genetic buffering
The Potential Global Health Impact and Cost-effectiveness of Next-generation Influenza Vaccines: A Modelling Analysis
Nextgeneration influenza vaccines NGIVs are in development and have the potential to achieve substantial reductions in influenza burden with resulting widespread health and economic benefits
Biomarkers of mRNA Vaccine Efficacy Derived from Mechanistic Modeling of Tumor-immune Interactions
The success of mRNA vaccines against infectious diseases such as COVID has opened new avenues for their application in oncology In cancer immunotherapy mRNA vaccinestypically encapsulated in lipid nanoparticles LNPs
Features Influencing the Health and Economic Impact of Preventing COVID-19 in Immunocompromised Individuals
Many immunocompromised individuals mount inadequate immune responses following COVID vaccination thus relying on other social distancing behaviours particularly shielding for protection impacting their quality of life
Long-term Anti-SARS-CoV-2 Antibody Trajectories After Neutralizing Monoclonal Antibody Treatment
Neutralizing monoclonal antibodies nMAbs have been used to treat COVID and are increasingly being used to treat other infections However there is concern that by neutralizing the SARSCoV virus
Randomization in Clinical Trials With Small Sample Sizes Using Group Sequential Designs
Group sequential designs which allow early stopping for efficacy or futility may benefit from balanced sample sizes at interim and final analyses This requirement for balance limits the choice of admissible randomization procedures
Learning a Deep Language Model for Microbiomes: The Power of Large Scale Unlabeled Microbiome Data
We use open source human gut microbiome data to learn a microbial language model by adapting techniques from Natural Language Processing NLP Our microbial language model is trained in a selfsupervised fashion
Host Centric Drug Repurposing for Viral Diseases
Computational approaches for drug repurposing for viral diseases have mainly focused on a small number of antivirals that directly target pathogens virus centric therapies In this work we combine ideas from collaborative
Spatial Structure Facilitates Evolutionary Rescue by Drug Resistance
Bacterial populations often have complex spatial structures which can impact their evolution Here we study how spatial structure affects the evolution of antibiotic resistance in a bacterial population
